Squamous cell carcinoma of vulva Measurable | Lesion of vulva Assessment | Neoplasm Metastasis Measurable | Primary tumor | Recurrent tumor | Operative Surgical Procedures Planned | Chemotherapy | Therapeutic radiology procedure
Item
histologically confirmed measurable squamous cell carcinoma of the vulvar with an assessable lesion on the vulva or measurable metastatic disease. tumors may be primary or recurrent. patients must have plans for surgery or definitive treatment with chemotherapy +/-radiation unless they have measurable metastatic disease.
boolean
C0280856 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C0221784 (UMLS CUI [2,1])
C1516048 (UMLS CUI [2,2])
C0027627 (UMLS CUI [3,1])
C1513040 (UMLS CUI [3,2])
C0677930 (UMLS CUI [4])
C0521158 (UMLS CUI [5])
C0543467 (UMLS CUI [6,1])
C1301732 (UMLS CUI [6,2])
C0392920 (UMLS CUI [7])
C1522449 (UMLS CUI [8])
Age
Item
18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Chemotherapy Absent | Therapeutic radiology procedure Absent
Item
no concurrent chemotherapy or radiotherapy
boolean
C0392920 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Prior Chemotherapy Absent | Prior radiation therapy Absent
Item
no previous chemotherapy or radiotherapy within the preceding 1 month
boolean
C1514457 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0279134 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status of 0-1
boolean
C1520224 (UMLS CUI [1])
Hypersensitivity erlotinib
Item
known hypersensitivity reaction to erlotinib
boolean
C0020517 (UMLS CUI [1,1])
C1135135 (UMLS CUI [1,2])
Malignant Neoplasms | Basal cell carcinoma Excluded
Item
other coexisting malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2,1])
C2828389 (UMLS CUI [2,2])
Drugs, Non-Prescription | Investigational New Drugs
Item
treatment with a non-fda approved or investigational drug within 30 days
boolean
C0013231 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Prior Therapy | Toxicity persistent CTCAE Grades | Alopecia | Lymphedema
Item
persistent toxicities (grade 2 or above) from previous treatment, expect alopecia or lymphedema
boolean
C1514463 (UMLS CUI [1])
C0600688 (UMLS CUI [2,1])
C0205322 (UMLS CUI [2,2])
C1516728 (UMLS CUI [2,3])
C0002170 (UMLS CUI [3])
C0024236 (UMLS CUI [4])
Creatinine measurement, serum | CTCAE Grades
Item
serum creatinine level greater than ctc grade 2
boolean
C0201976 (UMLS CUI [1])
C1516728 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnancy or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Systemic disease Severe | Systemic disease Uncontrolled
Item
severe or uncontrolled systemic disease
boolean
C0442893 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0442893 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
Disease Study Subject Participation Status At risk | Laboratory test finding Study Subject Participation Status At risk
Item
significant clinical disorder or laboratory finding that makes it potentially unsafe for the subject to participate
boolean
C0012634 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C0587081 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1444641 (UMLS CUI [2,3])